How to buy evantumumab in China

As the world's first approved EGFR/cMET bispecific antibody drug, amivantamab (amivantamab-vmjw) brings new hope to patients with advanced or metastatic non-small cell lung cancer (NSCLC) who carry EGFR exon 20 insertion mutations and whose disease has progressed after platinum-based chemotherapy. However, as of now, evantumumab has not officially entered the Chinese market.

The launch time of a drug is often affected by multiple complex factors such as the progress of clinical trials and the approval process of regulatory agencies. Therefore, it is currently impossible to predict its specific launch time in the Chinese market. However, all parties are actively promoting this process in order to benefit Chinese patients as soon as possible.

In the phase 2 clinical trial of evantumumab, researchers selected the recommended dose based on the target saturation of serum EGFR and MET, and the established preclinical concentration of 168ug/mL. When the dose exceeds 700 mg, circulating indicators of EGFR and methionine can reach saturation. To minimize pharmacokinetic variability, the dose of the drug is adjusted based on the patient's weight. For patients weighing 80 kg and above, the recommended dose is 1400 mg; for patients weighing less than 80 kg, the recommended dose is 1050 mg. This weight-based graded dosing method effectively adapts to the drug distribution and clearance needs of patients of different weights.

It is worth noting that evantuzumab is a prescription drug and must be used under the guidance of a doctor. Only physicians with extensive experience in treating cancer drugs should prescribe them and should be used in an environment where any infusion-related side effects can be managed promptly. The drug is administered as an intravenous infusion, with doses divided into two consecutive days for the first week, then weekly for the next three weeks, and then every two weeks.